IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells

EGFR-mutated non-small cell lung cancer patients experience relapse within 1-2 years of treatment with EGFR-inhibitors, such as erlotinib. Multiple resistance mechanisms have been identified including secondary EGFR-mutations, MET-amplification, and epithelial-mesenchymal transition (EMT). Previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussmann, Dianna, Madsen, Anne Tranberg, Jakobsen, Kristine Raaby, Luo, Yonglun, Sorensen, Boe Sandahl, Nielsen, Anders Lade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464869/
https://www.ncbi.nlm.nih.gov/pubmed/28418902
http://dx.doi.org/10.18632/oncotarget.16350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464869/
https://www.ncbi.nlm.nih.gov/pubmed/28418902
http://dx.doi.org/10.18632/oncotarget.16350

Ejemplares similares